Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy.

作者： Eugene R. Ahn , Emilie Wang , Stefan Glück

关键词:

摘要: Following FDA approval of trastuzumab in 1998 and lapatinib 2007, several clinical studies have addressed the question whether combination therapy is better than alone metastatic breast cancer neoadjuvant setting. In this review, updated to September 2012, we focus on relevant trials that address and, based available data, reach conclusions regarding a rational reasonably individualized approach management HER2+ cancer. With pertuzumab June 2012 likely T-DM1 approaching, ethical issues overshadow excitement oncologists for these new treatment options. We discuss potential evolution highly active anti-HER2 (HAAHT) as an optimal paradigm Additionally, review lessons learned from HAART HIV treatment.

参考文章(90)

Soley Bayraktar, Ana M. Gonzalez-Angulo, Xiudong Lei, Aman U. Buzdar, Vicente Valero, Amal Melhem-Bertrandt, Henry M. Kuerer, Gabriel N. Hortobagyi, Aysegul A. Sahin, Funda Meric-Bernstam, Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. ,vol. 118, pp. 2385- 2393 ,(2012) , 10.1002/CNCR.26555

Kimberly L. Blackwell, David Miles, Luca Gianni, Ian E Krop, Manfred Welslau, José Baselga, Mark D. Pegram, Do-Youn Oh, Veronique Dieras, Steven R. Olsen, Liang Fang, Michael W Lu, Ellie Guardino, Sunil Verma, Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. Journal of Clinical Oncology. ,vol. 30, pp. LBA1- LBA1 ,(2012) , 10.1200/JCO.2012.30.15_SUPPL.LBA1

Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073

Norma O’Donovan, Annette T. Byrne, Aisling E. O’Connor, Sharon McGee, William M. Gallagher, John Crown, Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. Investigational New Drugs. ,vol. 29, pp. 752- 759 ,(2011) , 10.1007/S10637-010-9415-5

Teemu T. Junttila, Robert W. Akita, Kathryn Parsons, Carter Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski, Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Cancer Cell. ,vol. 15, pp. 429- 440 ,(2009) , 10.1016/J.CCR.2009.03.020

Wenle Xia, Catherine M Gerard, Leihua Liu, Nathalie M Baudson, Thierry L Ory, Neil L Spector, Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells Oncogene. ,vol. 24, pp. 6213- 6221 ,(2005) , 10.1038/SJ.ONC.1208774

Gottfried E. Konecny, Giovanni Pauletti, Michael Untch, He-Jing Wang, Volker Möbus, Walther Kuhn, Christoph Thomssen, Nadia Harbeck, Ling Wang, Sophia Apple, Fritz Jänicke, Dennis J. Slamon, Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer Breast Cancer Research and Treatment. ,vol. 120, pp. 481- 489 ,(2010) , 10.1007/S10549-010-0744-Z

Edith A. Perez, Maria Koehler, Julie Byrne, Alaknanda J. Preston, Erica Rappold, Michael S. Ewer, Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials Mayo Clinic Proceedings. ,vol. 83, pp. 679- 686 ,(2008) , 10.4065/83.6.679

Michael S. Glickman, Charles L. Sawyers, Converting Cancer Therapies into Cures: Lessons from Infectious Diseases Cell. ,vol. 148, pp. 1089- 1098 ,(2012) , 10.1016/J.CELL.2012.02.015

10.

Wenle Xia, Robert J Mullin, Barry R Keith, Lei-Hua Liu, Hong Ma, David W Rusnak, Gary Owens, Krystal J Alligood, Neil L Spector, Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Oncogene. ,vol. 21, pp. 6255- 6263 ,(2002) , 10.1038/SJ.ONC.1205794

Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy.

来源期刊

我的账户

Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy.

来源期刊

相似文章 10

我的账户